Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 6, 2005 - Issue 11
Submit an article Journal homepage
87
Views
2
CrossRef citations to date
0
Altmetric
Drug Evaluation

Fluvastatin: efficacy and safety in reducing cardiac events

Mark Y Chan The Heart Institute, National University Hospital, Singapore, Level 3, Main Building, 5 Lower Kent Ridge Road, 119074 Singapore. [email protected]
&
Chi Hang Lee The Heart Institute, National University Hospital, Singapore, Level 3, Main Building, 5 Lower Kent Ridge Road, 119074 Singapore. [email protected]
Pages 1883-1895 | Published online: 07 Sep 2005

Bibliography

  • NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III): Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation (2002) 106(25):3143–3421.
  • NISSEN SE, TUZCU EM, P et al.: Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease: N EngL J. Med. (2005) 352(1):29–38.
  • LAROSA JC, HE J, VUPPUTURI S: Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA (1999) 282(24):2340–2346.
  • CORSINI A: Fluvastatin: effects beyond cholesterol lowering. J. Cardiovasc. PharmacoL Ther. (2000) 5(3):161–175.
  • HEART PROTECTION STUDY COLLABORATIVE GROUP: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 360(9326):7–22.
  • SHEPHERD J, BLAUW GJ, MB et aL: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet (2002) 360(9346):1623–1630.
  • ALLHAT OFFICERS AND FOR THE ALLHAT COLLABORATIVE RESEARCH GROUP: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA (2002) 288(23):2998–3007.
  • SEVER PS, DAHLOF B, POULTER NR et aL: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet (2003) 361(9364):1149–1158.
  • CANNON CP, BRAUNWALD E, MCCABE CH et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N EngL J. Med. (2004) 350(15):1495–1504.
  • LAROSA JC, GRUNDY SM, DD et aL: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl. J. Med. (2005) 352(14):1425–1435.
  • COLHOUN HM, BETTERIDGE DJ, DURRINGTON PN et aL: Primary of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet (2004) 364(9435):685–696.
  • BALLANTYNE CM, ABATE N, YUAN Z, KING TR, PALMISANO J: Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am. Heart J. (2005) 149(3):464–473.
  • WILLIAMS B, POULTER NR, BROWN MJ et al.: Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV J. Hum. Hypertens. (2004) 18(3):139–185.
  • CONROY RM, PYORALA K, AP et al: Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur. Heart J. (2003) 24(11):987–1003.
  • FORD ES: Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care (2005) 28(7):1769–1778.
  • DE LEMOS JA, BLAZING MA, SD et al.: Early intensive versus a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 292(11):1307–1316.
  • WIERZBICKI AS, MIKHAILIDIS DP, R et al.: Statin-fibrate combination: therapy for hyperlipidemia: a review. Curr. Med. Res. Opin. (2003) 19(3):155–168.
  • NOVARTIS PHAMACEUTICALS CORPORATION: Lescole and Lescol XL (fluvastatin sodium) prescribing information. Novartis Phamaceuticals Corporation, East Hanover, NJ, USA (2003).
  • JOKUBAITIS LA: Development and pharmacology of fluvastatin. Br. J. CAn. Pract. (1996) 77 A(Suppl.): 11–15.
  • YAMAMOTO A, ICHIHARA K, HOSHI K: Antioxidative effect of fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on peroxiclation of phospholipid liposomes. Pharm. Pharmacol (2001) 53(2):227–232.
  • SUZUMURA K, OHASHI N, OKA K, YASUHARA M, NARITA H: Fluvastatin depresses the enhanced lipid peroxidation in vitamin E-deficient hamsters.. Radic. Res. (2001) 35(6):815–823.
  • BAETTA R, CAMERA M, COMPARATO C, ALTANA C, EZEKOWITZ MD, TREMOLI E: Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in the absence of lipid lowering. Arterioscler. Thromb. Vase. Biol. (2002) 22(4):692–698.
  • SUZUMURA K, YASUHARA M, TANAKA K, SUZUKI T: Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro.. Pharmacol (1999) 57(61:697–703.
  • CHI DS, JIN FX, YANG SG et al: [Effects of fluvastatin on the levels of C-reactive protein and lipids in patients with hyperlipidemia]. Di Yi Jun Yi Da Xue Xue Bao (2002) 22(12):1109–1111.
  • VAN HAELST PL, VAN DOORMAAL JJ, MAY JF, GANS RO, CRIJNS HJ, COHEN TERVAERT JW: Secondary prevention with fluvastatin decreases levels of adhesion molecules, neopterin and C-reactive protein. Eur. J. Intern. Med. (2001) 12(6):503–509.
  • MUSSONI L, BANFI C, SIRONI L, ARPAIA M, TREMOLI E: Fluvastatin inhibits basal and stimulated plasminogen activator inhibitor 1, but induces tissue type plasminogen activator in cultured human endothelial cells. Thromb. Haemost. (2000) 84(1):59–64.
  • KIMURA M, KUROSE I, RUSSELL J, GRANGER DN: Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats.. Thromb. Vase. Biol. (1997) 17(8):1521–1526.
  • ZHANG B, NODA K, MATSUNAGA A, KUMAGAI K, SAKU K: A comparative crossover study of the effects of fluvastatin and pravastatin (FP-COS) on circulating autoantibodies to oxidized LDL in patients with hypercholesterolemia.. Atheroscler. Thromb. (2005) 12(1):41–47.
  • BELL J, CAGE VM: Fluvastatin: pharmakokinetic properties. J. (1995) 22(2):184–186.
  • DESLYPERE JP: Clinical implications of the biopharmaceutical properties of fluvastatin. Am. J. Cardiol. (1994) 73(14):12D-17D.
  • FISCHER V JOHANSON L, HEITZ F et al.: The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P450 and implications for metabolic drug interactions. Drug. Metab. Dispos. (1999) 27(3):410–416.
  • TRANSON C, LEEMANN T, VOGT N, DAYER P: In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-) fluvastatin. Clin. Pharmacol Ther. (1995) 58(4):412–417.
  • PRUEKSARITANONT T, SUBRAIVIANIAN R, FANG X et al: Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug. Metab. Dispos. (2002) 30(5):505–512.
  • TSE FL, NICKERSON DF, YARDLEY WS: Binding of fluvastatin to blood cells and plasma proteins. Pharm. Sci. (1993) 82(9):942–947.
  • TRILLI LE, KELLEY CL, ASPINALL SL, KRONER BA: Potential interaction between warfarin and fluvastatin. Ann. Pharmacother. (1996) 30(12):1399–1402.
  • ANDRUS MR: Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature. Pharmacotherapy (2004) 24(2):285–290.
  • SMIT JW, WIJNNE HJ, SCHOBBEN F, SITSEN A, DE BRUIN TW, DW: Effects of alcohol consumption on pharmacokinetics, efficacy, and safety of fluvastatin. Am. J. Cardiol (1995) 76(2):89A-96A.
  • SABIA H, PRASAD P, SMITH HT, STOLTZ RR, ROTHENBERG P: Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia.. Pharmacol (2001) 37(5):502–511.
  • JONES P, KAFONEK S, LAURORA I, HUNNINGHAKE D: Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am. J. Cardiol (1998) 81(5):582–587.
  • SCHAEFER EJ, MCNAMARA JR, TAYLER T et al.: Comparisons of effects statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.. J. CardioL (2004) 93(1):31–39.
  • JONES PH, DAVIDSON MH, STEIN EA et al.: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am. J. CardioL (2003) 92(2):152–160.
  • BALLANTYNE CM, PAZZUCCONI F, PINTO X et al.: Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis.. Ther. (2001) 23(2):177–192.
  • YUAN JN, TSAI MY, HEGLAND J, HUNNINGHAKE DB: Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans. Atherosclerosis (1991) 87(2-3):147–157.
  • TSE FL, JAFFE JM, TROENDLE A: Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J. Clin. PharmacoL (1992) 32(7):630–638.
  • DAIN JG, FU E, GORSKI J, NICOLETTI J, SCALLEN TJ: Biotransformation of fluvastatin sodium in humans. Drug. Metab. Dispos. (1993) 21(4):567–572.
  • HAYASHI K, KUROKAWA J, NOMURA S, KUGA Y, OHKURA Y, KAJIYAMA G: Effect of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on the induction of low-density lipoprotein receptor in HepG2 cells. Biochim. Biophys. Acta (1993) 1167(2):223–225.
  • DUJOVNE CA, DAVIDSON MH: Fluvastatin administration at bedtime versus with the evening meal: a multicenter comparison of bioavailability, safety, and efficacy. Am. J. Med. (1994) 96(6A):375–405.
  • SMIT JW, JANSEN GH, DE BRUIN TW, ERKELENS DW: Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage. Am. J. CardioL (1995) 76(2):126A-128A.
  • SPIEKER LE, NOLL G, HANNAK M, LUSCHER TF: Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high levels. J. Cardiovasc. PharmacoL (2000) 35(3):361–365.
  • SUZUMURA K, YASUHARA M, NARITA H: Superoxide anion scavenging properties of fluvastatin and its metabolites. Chem. Pharm. Bull. (1999) 47(10):1477–1480.
  • JACOBSON TA, CHIN MM, FROMELL GJ, JOKUBAITIS LA, AMOROSA LF: Fluvastatin with and without niacin for hypercholesterolemia. Am. J. CardioL (1994) 74(2):149–154.
  • JACOBSON TA, AMOROSA LF: Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety. Am. J. CardioL (1994) 73(14):25D-29D.
  • LEITERSDORF E, MURATTI EN, ELIAV O, PETERS TK: Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia. Am. J. CardioL (1995) 76(2):84A-88A.
  • LEITERSDORF E, EISENBERG S, ELIAV 0 et al.: Efficacy and safety of high dose fluvastatin in patients with familial hypercholesterolaemia. Eur J. Clin. PharmacoL (1993) 45(6):513–518.
  • KOIZUMI J, HARAKI T, YAGI K et aL:Clinical efficacy of fluvastatin in the long-term treatment of familial hypercholesterolemia. Am. J. CardioL (1995) 76(2):47A-50A.
  • JOKUBAITIS LA: Fluvastatin in combination with other lipid-lowering agents. Br. J. Clin. Pract. (1996) 77A:(Suppl.) 28–32.
  • MURATTI EN, PETERS TK, E: Fluvastatin in familial hypercholesterolemia: a cohort analysis of the response to combination treatment. Am. J. CardioL (1994) 73(14):30D-38D.
  • APPEL S, RUFENACHT T, G et al.: Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus. Am. J. CardioL (1995) 76(2):29A-32A.
  • LANGTRY HD, MARKHAM A: Fluvastatin: a review of its use in lipid disorders. Drugs (1999) 57(4):583–606.
  • PETERS TK, MEHRA M, EN: Efficacy and safety of fluvastatin in hypertensive patients. An analysis of a clinical trial database.. J. Hypertens. (1993) 6(11 Pt 2):3405–3455.
  • PETERS TK, MURATTI EN, MEHRA M: Efficacy and safety of fluvastatin in women with primary hypercholesterolaemia. Drugs ( 1994) 47(Suppl.):264–272.
  • BAGGIO G, DE CANDIA O, FORTE PL et al.: Efficacy and safety of fluvastatin, a new HMG CoA reductase inhibitor, in elderly hypercholesterolaemic women. Drugs (1994) 47(Suppl.):259–263.
  • BRUCKERT E, LIEVRE M, GIRAL P et al.: Short-term efficacy and safety of extended-release fluvastatin in a large cohort of elderly patients. Am. J. Geriatr. CardioL (2003) 12(4):225–231.
  • LYE M, VALACIO R, RECKLESS JP et al.: Elderly patients with hypercholesterolaemia: a double-blind study of the efficacy, safety and tolerability of fluvastatin.. Artery Dis. (1998) 9(9):583–590.
  • TOMLINSON B, MAK TW, TSUI JY et al.: Effects of fluvastatin on lipid profile and apolipoproteins in Chinese patients with hypercholesterolemia. Am. J. CardioL (1995) 76(2):136A-139A.
  • TERAMOTO T, GOTO Y, K et al.: Clinical efficacy of fluvastatin for hyperlipidemia in Japanese patients. Am. J. CardioL (1995) 76(2):33A-36A.
  • TANAKA M, ITOH K, MATSUSHITA K, KITAMURA K, NONOGUCHI H, TOMITA K: [Effects of fluvastatin on plasma lipid abnormalities in hemodialysis patients with chronic renal failure]. Nippon Jinzo Gakkai Shi (2002) 44(4):402–408.
  • SAMUELSSON O, ATTMAN PO, KNIGHT-GIBSON C, MULEC H, WEISS L, ALAUPOVIC P: Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency. Am. J. Kidney. Dis. (2002) 39(1):67–75.
  • YASUDA G, KUJI T, HASEGAWA K et al.: Safety and efficacy of fluvastatin in hyperlipidemic patients with chronic renal disease. Ren. Fail. (2004) 26(4):411–418.
  • BENESIC A, ZILLY M, KLUGE F et al.: Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir. Infection (2004) 32(4):229–233.
  • TOKUMOTO T, TANABE K, ISHIDA H et al.: Impact of fluvastatin on hyperlipidemia after renal transplantation. Transplant. Proc. (2004) 36(7):2141–2144.
  • AMBROSI P, AILLAUD MF, HABIB G et al.: Fluvastatin decreases soluble thrombomodulin in cardiac transplant recipients. Thromb. Haemost. (2000) 83(1):46–48.
  • RIEGGER G, ABLETSHAUSER C, LUDWIG M et aL: The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. (1999) 144(1):263–270.
  • HERD JA, BALLANTYNE CM, FARMER JA et al.: Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am. J. CardioL (1997) 80(3):278–286.
  • HERD JA, WEST MS, BALLANTYNE C, FARMER J, GOTTO AM Jr: Baseline characteristics of subjects in the Lipoprotein and Coronary Atherosclerosis Study (LCAS) with fluvastatin. Am. J. CardioL (1994) 73(14):42D-49D.
  • HOLDAAS H, FELLSTROM B, JARDINE AG et al.: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. (2003) 361(9374):2024–2031.
  • SERRUYS PW, FOLEY DP, JACKSON G et al.: A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur. Heart J. (1999) 20(1):58–69.
  • SERRUYS PW, DE FEYTER P, MACAYA C et al.: Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA (2002) 287(24):3215–3222.
  • LIEM AH, VAN BOVEN AJ, VEEGER NJet al.: Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial. Eur. Heart J. (2002) 23(24):1931–1937.
  • HEDBLAD B, WIKSTRAND J, JANZON L, WEDEL H, BERGLUND G: Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Plaque Study (BCAPS). Circulation (2001) 103(13):1721–1726.
  • ANDERSSEN SA, HJELSTUEN AK, HJERMANN I, BJERKAN K, HOLME I: Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives. Atherosclerosis (2005) 178(2):387–397.
  • VAN DAM MJ, PENN HJ, DEN HARTOG FR et al.: A comparison of the efficacy and tolerability of titrate-to-goal regimens of simvastatin and fluvastatin: a randomized, double-blind study in adult patients at moderate to high risk for cardiovascular disease. Clin. Ther. (2001) 23(3):467–478.
  • JACOTOT B, BENGHOZI R, P, HOLMES D: Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. French Fluvastatin Study Group. Am. J. CardioL (1995) 76(2):54A-56A.
  • PSATY BM, FURBERG CD, RAY WA, WEISS NS: Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. JAMA (2004) 292(21):2622–2631.
  • LUH JY, KARNATH BM: Issues in statin-associated myopathy. JAMA (2003) 290(7):888; Author reply 888–889.
  • HYMAN MH: Issues in statin-associated myopathy. JAMA (2003) 290(7):888; Author reply 888–889.
  • THOMPSON PD, CLARKSON P, KARAS RH: Statin-associated myopathy. JAMA (2003) 289(13):1681–1690.
  • BALLANTYNE CM, CORSINI A, DAVIDSON MH et al.: Risk for myopathy with statin therapy in high-risk patients. Arch. Intern. Med. (2003) 163(5):553–564.
  • BENGHOZI R, BORTOLINI M, JIAY, ISAACSOHN JL, TROENDLE AJ, GONASUN L: Frequency of creatine kinase elevation during treatment with fluvastatin. Am. J. CardioL (2002) 89(2):231–233.
  • OMAR MA, WILSON JP: FDA adverse event reports on statin-associated rhabdomyolysis. Ann. Pharmacother. (2002) 36(2):288–295.
  • SPENCE JD, MUNOZ CE, HENDRICKS L, LATCHINIAN L, KHOURI HE: Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am. J. CardioL (1995) 76(2):80A-83A.
  • FARNIER M, BORTOLINI M, SALKO T et al.: Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil). Am. J. CardioL (2003) 91(2):238–240.
  • ASBERG A. HOLDAAS H: Fluvastatin and fluvastatin extended release: a clinical and safety profile. Expert Rev. Cardiovasc. Ther. (2004) 2(5):641–652.
  • SICA DA, GEHR TW: Rhabdomyolysis and statin therapy: relevance to the elderly. Am. J. Geriatr. Cardiol. (2002) 11(1):48–55.
  • MARCUS EL, RUDENSKY B, SONNENBLICK M: Occult elevation of CK as a manifestation of rhabdomyolysis in the elderly./ Am. Geriatr. Soc. (1992) 40(5):454–456.
  • HADJIGAVRIEL M, KYRIAKIDES G: Fluvastatin in renal transplantation. Transplant. Proc. (1997) 29(7):3050.
  • LOCSEY L, ASZTALOS L, KINCSES Z, BALAZS G: Fluvastatin (Lescol) treatment of hyperlipidaemia in patients with renal transplants. Int. UroL Nephrol. (1997) 29(1):95–106.
  • LAL SM, GUPTA N, GEORGIEV O, ROSS G Jr: Lipid-lowering effects of fluvastatin in renal transplant patients. A clinical observation.. J. Artif Organs (1997) 20(1):18–21.
  • ICHIHARA A, HAYASHI M, M, HANDA M, T, SARUTAT: Fluvastatin prevents development of arterial stiffness in haemodialysis patients with Type 2 diabetes mellitus. Nephrol. DiaL Transplant. (2002) 17(8):1513–1517.

Websites

  • www.nhlbi.nih.gov/guidelines/cholesterol National Institute of Health 10-year risk calculator. 28 July, 2005.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.